Takeda Aims for ¥200B in Annualized Savings by FY28 Through Business Transformation and Restructuring

Takeda Pharmaceutical plans to generate ¥200B ($1.3B) in annualized gross savings by FY28 through a business transformation exercise and restructuring drive. The company aims to achieve this by cutting costs and improving efficiency. Takeda's board of directors approved the plan, which is expected to help the drugmaker navigate the challenging pharmaceutical industry.